Given the increasing use of frontline lenalidomide-based therapies in multiple myeloma
(MM), there is an emerging need for lenalidomide-sparing regimens at relapse. Carfilzomib …

Introduction: Lenalidomide is increasingly used for the treatment of newly diagnosed
multiple myeloma. However, most patients experience relapse during treatment or after …

Background With increasing utilization of immunomodulatory agents (particularly
lenalidomide) for the management of newly diagnosed multiple myeloma, there is an …

Background Lenalidomide and bortezomib frontline exposure has raised a growing need for
novel treatments for patients with relapsed or refractory multiple myeloma. Carfilzomib in …

Methods All patients received≥ 1 prior line of therapy (LOT) and were administered 8 cycles
(Q3W) of Vd (Days 1, 4, 8, 11 for bortezomib 1.3 mg/m 2 SC; Days 1-2, 4-5, 8-9, and 11-12 …

INTRODUCTION. Recent studies show that~ 25% of newly diagnosed multiple myeloma
patients treated with 8 cycles of bortezomib, lenalidomide and dexamethasone (VRd) …

Introduction: The use of lenalidomide (LEN) and bortezomib (BTZ) in newly diagnosed
multiple myeloma (MM) patients (pts), along with continuous or maintenance therapy …

Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …

Methods Patients with≥ 1 prior LOT were randomized (1: 1) to receive Rd (lenalidomide 25
mg PO on Days 1-21; dexamethasone 40 mg PO weekly)±daratumumab (16 mg/kg IV once …

INTRODUCTION. Bortezomib, lenalidomide and dexamethasone (VRd) is considered a
standard of care combination therapy for newly diagnosed multiple myeloma patients. Prior …